MESSAGE FROM THE ACTING EXECUTIVE DIRECTOR
2021 has been another extraordinary year. It’s been a year defined by the COVID-19 pandemic and the significant changes to our work and personal lives. We have again been asked to demonstrate considerable flexibility and resilience, and I’ve been tremendously impressed by the efforts and commitment of our team throughout the year. Despite the changes over the last 12 months, it’s been a remarkable year for the Kolling. We kicked off the year with the launch of the institute’s strategy, a blueprint to strengthen our ability to achieve ground breaking research. The strategy involves a host of initiatives to increase the impact of our research and shape the future of the institute. I would like to thank the large number of people who have been involved in the development of the strategic framework this year, as well as the many members of the priority research area and research enabler committees. Thank you for sharing your time and expertise to help us achieve substantial progress this year and help secure our long- term success.
2021 has seen members of our team drive nationally and internationally significant research and directly influence patient outcomes. Importantly this progress has been made across all our priority research areas of neuroscience and pain, musculoskeletal, and cardiovascular and renal research. We are influencing patient treatments, health policy, and crucially, raising the level of care our community receives. Our efforts have been recognised with a range of prestigious honours and significant funding including National Health and Medical Research Council grants – some of which are featured in this newsletter – state government funds and philanthropic support. There is tremendous expertise and experience across the Kolling and it’s encouraging to see our track record consistently recognised. As we reflect on the achievements this year and plan for 2022, we expect to see a greater focus on strengthening our existing partnerships and establishing new ones. We anticipate there will be further collaborations across our priority research areas, as well as with industry, government
and a growing body of consumer partners. All of these partnerships hold the key to large-scale, multidisciplinary research success and substantial improvements in patient care, and further efforts will be invested in fostering these relationships. I would like to commend everyone for their contribution this year and wish you all a wonderful break over the holiday period. I would also like to welcome back Executive Director Professor Carolyn Sue who will be returning from leave in the new year. We look forward to your return.
Warm regards
Jim Professor Jim Elliott Acting Executive Director
2
KOLLINGNEWS | DECEMBER 2021
Made with FlippingBook - professional solution for displaying marketing and sales documents online